What OATS and mosaicplasty actually involve

During an OATS procedure, a surgeon takes one or more small cylindrical plugs — each comprising a column of bone topped with its native cartilage surface — from a part of the knee that bears relatively little load, typically the margins of the femoral notch. Those plugs are then press-fitted, in a single operating session, directly into the base of the damaged area. No cell culture, no second operation, no waiting for laboratory results.

The tissue being transplanted matters enormously. What arrives at the repair site is genuine hyaline cartilage — the same dense, structured material that lines a healthy joint. By contrast, microfracture works by puncturing the subchondral bone to trigger a blood-clot response; the tissue that forms from that clot is fibrocartilage, a mechanically weaker material that degrades more readily under the repetitive high-impact loads of an active life.

Arthroscopic versus open delivery

For smaller lesions — roughly under 1 cm² — the procedure can be performed arthroscopically through keyhole incisions, which is associated with fewer complications. Larger defects require an open approach, which allows the surgeon to place multiple plugs side by side in what is called a mosaicplasty arrangement; open OAT can address lesions up to approximately 5 cm² in this way, around three times the area manageable through the arthroscope.

The medial femoral condyle is the most common treatment site, accounting for roughly 75% of cases. Patellofemoral defects can be addressed with this technique, but donor-site morbidity is higher and outcomes are generally less favourable, so location is factored carefully into the pre-operative assessment.

One nuance worth understanding with the multi-plug mosaicplasty approach: the small gaps between adjacent plugs tend to fill with fibrocartilage rather than hyaline tissue. The dominant graft surface remains hyaline cartilage, but the inter-plug areas are not, which is relevant context when weighing the technique against alternatives that aim for complete hyaline coverage.

Who is likely to be offered OATS

Most specialists will want to know a few key things before considering OATS: your age, your BMI, the precise size and location of the defect, how much background arthritis is present, and whether non-surgical options have already been tried. These factors guide — but do not guarantee — selection, and individual anatomy and activity goals always play a part in the final decision.

Age and activity level

The strongest evidence for OATS sits in patients under 40. A 2024 ScienceDirect analysis confirmed that outcomes are significantly better in this age group compared with those over 40, making younger active adults the clearest beneficiaries. That said, many surgeons will consider the procedure up to around 50, particularly for patients who are otherwise fit and have a well-contained defect.

Defect size and location

Arthroscopic OAT is generally suited to contained focal lesions of roughly 1–2.5 cm². When a larger area needs covering — up to approximately 5 cm² — an open mosaicplasty approach using multiple plugs becomes the relevant option. Diffuse or widespread cartilage loss is outside the scope of this technique; it points toward joint-preservation or replacement discussions instead. As noted in the previous section, the medial femoral condyle is the most frequently treated site, and patellofemoral defects carry less favourable results.

BMI, arthritis grade, and joint health

A BMI below 40 is a common requirement. Excess load accelerates stress on the transferred plugs and may compromise how well they integrate. On the arthritis side, Kellgren-Lawrence OA grade 2 or below is the accepted threshold; beyond that, the background joint environment is likely too hostile for a focal repair to hold. Inflammatory arthritis — rheumatoid, psoriatic, or similar — is a contraindication, as the systemic inflammation would not support survival of the transplanted cartilage.

Functional outcomes and how long results last

Sixty per cent of patients in the most detailed long-term cohort still exceeded the IKDC minimal clinically important difference at ten years — a benchmark that represents genuine, patient-felt benefit, not merely a statistical shift. That figure anchors realistic expectations better than any single score point.

The recovery trajectory over ten years

The published score sequence from a 63-patient institutional registry (mean age 27.4 years, mean lesion size 2.3 cm²) traces a clear arc. Before surgery, mean IKDC scores sat at 46.4 — a level associated with meaningful pain and restricted activity. By two years, the mean had risen to 76.1, and by five years to 78.0. At ten years the figure settled at 70.4, all comparisons with the pre-operative baseline remaining statistically significant (p<.001).

That late dip from 78 to 70 reflects a real, modest decline rather than a return toward pre-operative levels. It matters clinically: OATS is not a permanent cure for all patients, and for some it may function as a durable bridge rather than a lifelong solution. Being direct about this is more useful than leaving it vague.

KOS-ADLS scores — which capture how well patients manage everyday physical tasks — tell a slightly more reassuring story. Rising from 64.4 before surgery to 83.2 at two years and 85.1 at five, they held at 83.8 at ten years. Daily function, in other words, remains broadly stable across the decade even as the headline IKDC score eases slightly.

Reoperation and arthroplasty conversion

Reoperation occurred in 28.6% of the cohort, though the majority of those procedures were minor — partial meniscectomy or chondroplasty rather than major revision surgery. Only two of the 63 patients required conversion to arthroplasty at mean five-year follow-up, a low rate given the decade-long window. Gudas et al., drawing on a separate patient group, corroborated the medium-term picture with 86–90% good or excellent results at three years.

Return to sport — what active patients can expect

For many active patients, the question that matters most is a practical one: will I get back to my sport, and at the same level as before?

Based on systematic review data — including the Campbell et al. analysis of OAT outcomes — 75–93% of young active patients return to their pre-injury sport following OATS, typically within 6–9 months, provided rehabilitation milestones are met. That range reflects genuine variability: defect size, surgical approach, and the physical demands of the sport all influence where within that window a patient lands.

The distinction between returning to any sport and returning to the same competitive or performance level is clinically important. The figures above refer to prior level — resuming the sport as previously played, not simply returning to light activity.

On this metric, OATS consistently outperforms microfracture in head-to-head comparisons; the Campbell et al. systematic review confirmed significantly higher return-to-sport rates for OAT over alternative cartilage restoration techniques. For younger, higher-demand patients, that difference is one of the practical reasons OATS has become the preferred approach over marrow-stimulation surgery in this population.

The 75–93% return-to-prior-level figure, set alongside a 6–9 month typical timeline, gives active patients a realistic benchmark — not a guarantee, but a meaningful signal about what a successful outcome looks like for people whose goal is sustained physical activity.

OATS versus microfracture — what the survival data show

The clearest argument for choosing OATS over microfracture in younger active patients sits in the survival curves. In a comparative Kaplan-Meier study of 203 patients (OAT n=84, microfracture n=119), failure — defined here as falling below a pre-specified functional threshold or requiring major revision surgery, rather than any reoperation — occurred in 51% of OAT cases versus 66% with microfracture (p=0.01).

The more striking figure is the time dimension. Mean time to failure was 8.4 years for OAT compared with 4.0 years for microfracture — nearly double the functional lifespan. OAT held above 80% survival for the first seven years and remained above 60% at fifteen years. Microfracture, by contrast, fell below 80% survival within twelve months of surgery and below 60% by year three.

That divergence — one curve staying above 80% for seven years, the other dropping below it within the first year — forms the core of the current clinical consensus against microfracture as a first-line option in active patients. The tissue biology behind it was covered in the opening section: fibrocartilage, formed from a marrow stem-cell clot, degrades faster under load than the native hyaline cartilage that OATS transplants, and the functional result tracks that degradation.

There is a further downstream consideration. Microfracture punctures the subchondral bone plate, and where that plate is disturbed, subsequent cartilage restoration procedures may be technically harder or less successful — a meaningful consequence for any young patient who may need further treatment decades later.

Most of this comparative evidence is Level III rather than randomised controlled trial data, and matched athlete cohorts specifically remain under-studied. The survival signal, however, is consistent and statistically robust across the published literature.

Limitations to weigh and how to find a specialist

Harvesting plugs from the same knee is the limitation patients most often raise. Taking cylindrical grafts from low-load-bearing areas — such as the femoral notch margins — can produce localised discomfort or aching at the donor site, and in some cases this persists beyond the main recovery period. Reporting of donor-site symptoms is inconsistent across the published literature, which means precise frequency figures are hard to establish; the number of plugs harvested and individual anatomy both play a role.

Three further boundaries are worth naming plainly. Very long-term data — beyond fifteen years — remain sparse; how the procedure performs over three or four decades in a patient operated on at twenty-five is not yet well characterised. Most of the comparative evidence against microfracture is Level III observational data rather than randomised controlled trials in matched athlete populations, which limits the precision of head-to-head claims. And the modest decline in IKDC scores documented at ten years is an honest signal: OATS may function as a durable bridge for some patients rather than a permanent resolution — a proportion will, in time, require further intervention.

For patients with patellofemoral involvement, large diffuse lesions, or established osteoarthritis, OATS sits outside its optimal indication. Alternative pathways — including MACI, fresh osteochondral allograft, or osteotomy to correct alignment — merit discussion with a specialist who works across the full range of cartilage-restoration options.

Taken together, the evidence supports OATS as the strongest available single-stage autograft option for the right candidate — younger, active, with a contained femoral condyle defect — while being honest that it is not a guarantee, and that the decision involves weighing durability against real surgical trade-offs specific to each person's joint, lifestyle, and long-term goals.

Search MSK lists knee cartilage specialists across the UK who offer OATS and the broader range of joint-preservation procedures — filter by region and specialty to find a consultant suited to your situation.